Insights on the Injectables Global Market to 2026 - Upsurge in Demand for Convenient Drug Delivery is Driving Growth

News provided by

Jun 10, 2022, 16:00 ET

DUBLIN, June 10, 2022 /PRNewswire/ -- The "Global Injectables Market: Insights & Forecast with Potential Impact of COVID-19 (2022-2026)" report has been added to ResearchAndMarkets.com's offering.

The global injectables market is estimated to reach US$836.6 billion in 2026, progressing at a CAGR of 10.95%, over the period 2022-2026.

Factors such as increasing geriatric population, upsurge in demand for convenient drug delivery, expanding use of biologics, rising healthcare expenditure and surging incidence of cancer cases would drive the growth of the market. However, the market growth would be challenged by stringent regulatory guidelines, emergence of alternative drug delivery methods and manufacturing complexity and high operational cost. A few notable trends may include accelerating prevalence of chronic diseases, growing adoption of self-injectable devices, upswing in drug shortages and advancements in technology.

Depending on the type, the global injectables market can be bifurcated into two main categories: innovator and generic. Further, generic injectables market can be split into Anti-Infectives (AI), Antineoplastics + Immunomodulators (AN+IM), Alimentary Tract + Metabolic (AT+Mb), Blood Related (BR), Central Nervous System (CNS), Musculoskeletal (Msk) and others, on the basis of therapy.

Scope of the report

The report provides a comprehensive analysis of the global injectables market segmented on the basis of type and region
The major regional and country markets (North America, Europe, China, India and Rest of the World) have been analyzed.
The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
The competitive landscape of the market, along with the company profiles of leading players (Novartis International AG, Pfizer Inc., Fresenius SE & Co. KGaA, Baxter International Inc., Shanghai Fosun Pharmaceutical Group Co. Ltd. (Gland Pharma Ltd.) and Hikma Pharmaceuticals PLC) are also presented in detail

Key Topics Covered:

1. Introduction

2. Impact of COVID-19
2.1 Growing Investments in the R&D Pipeline of Injectables
2.2 Surging Adoption of Plasma Therapy
2.3 Rising Usage of Smart Syringes
2.4 Accelerating Vaccine Production

3. Global Market Analysis
3.1 Global Injectables Market by Value
3.2 Global Injectables Market Forecast by Value
3.3 Global Injectables Market by Type
3.3.1 Global Innovator Injectables Market by Value
3.3.2 Global Innovator Injectables Market Forecast by Value
3.3.3 Global Generic Injectables Market by Value
3.3.4 Global Generic Injectables Market Forecast by Value
3.3.5 Global Generic Injectables Market by Therapy
3.3.6 Global Anti-Infective Injectables Market by Value
3.3.7 Global Anti-Infective Injectables Market Forecast by Value
3.3.8 Global Antineoplastic+ Immunomodulator Injectables Market by Value
3.3.9 Global Antineoplastic+ Immunomodulator Injectables Market Forecast by Value
3.3.10 Global Alimentary Tract + Metabolic Injectables Market by Value
3.3.11 Global Alimentary Tract + Metabolic Injectables Market Forecast by Value
3.3.12 Global Blood Related Injectables Market by Value
3.3.13 Global Blood Related Injectables Market Forecast by Value
3.3.14 Global Central Nervous System Injectables Market by Value
3.3.15 Global Central Nervous System Injectables Market Forecast by Value
3.3.16 Global Musculoskeletal Injectables Market by Value
3.3.17 Global Musculoskeletal Injectables Market Forecast by Value
3.4 Global Injectables Market by Region
3.5 Global Generic Injectables Market by Region

4. Regional Market Analysis

5. Market Dynamics
5.1 Growth Drivers
5.1.1 Increasing Geriatric Population
5.1.2 Upsurge in Demand for Convenient Drug Delivery
5.1.3 Expanding Use of Biologics
5.1.4 Rising Healthcare Expenditure
5.1.5 Surging Incidence of Cancer Cases
5.2 Key Trends and Developments
5.2.1 Accelerating Prevalence of Chronic Diseases
5.2.2 Growing Adoption of Self-Injectable Devices
5.2.3 Upswing in Drug Shortages
5.2.4 Advancements in Technology
5.3 Challenges
5.3.1 Stringent Regulatory Guidelines
5.3.2 Emergence of Alternative Drug Delivery Methods
5.3.3 Manufacturing Complexity & High Operational Cost

6. Competitive Landscape

7. Company Profiles
7.1 Novartis International AG
7.1.1 Business Overview
7.2 Pfizer Inc.
7.2.1 Business Overview
7.3 Fresenius SE & Co. KGaA
7.3.1 Business Overview
7.4 Baxter International Inc.
7.4.1 Business Overview
7.5 Shanghai Fosun Pharmaceutical Group Co. Ltd. (Gland Pharma Ltd.)
7.5.1 Business Overview
7.6 Hikma Pharmaceuticals PLC
7.6.1 Business Overview